Hypertension in the context of adiposity — indication assessment
Sustained elevation of arterial pressure above accepted diagnostic thresholds, considered here as a weight-responsive outcome rather than a primary treatment indication.
§1Assessment
§1.1Definition
Sustained elevation of arterial pressure above accepted diagnostic thresholds, considered here as a weight-responsive outcome rather than a primary treatment indication.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- Change in systolic and diastolic blood pressure
- Ambulatory blood-pressure monitoring change
- Antihypertensive medication burden
§1.3State of the evidence
The Institute assesses 1 compound in this indication, drawing on 0 trial records and 0 evidence syntheses. [1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.